Mismatch Repair Deficiency and Lynch Syndrome Among Adult Patients With Glioma

Archive ouverte

Benusiglio, Patrick, R | Elder, Fikret | Touat, Mehdi | Perrier, Alexandre | Sanson, Marc | Colas, Chrystelle | Guerrini-Rousseau, Lea | Tran, Duy Thanh | Trabelsi, Nesrine | Carpentier, Catherine | Marie, Yannick | Adam, Clovis | Bernier, Michèle | Cazals-Hatem, Dominique | Mokhtari, Karima | Tran, Suzanne | Mathon, Bertrand | Capelle, Laurent | Dhooge, Marion | Idbaih, Ahmed | Alentorn, Agusti | Houillier, Caroline | Dehais, Caroline | Hoang-Xuan, Khe | Cuzzubbo, Stefania | Carpentier, Antoine | Duval, Alex | Coulet, Florence | Bielle, Franck

Edité par CCSD ; American Society of Clinical Oncology -

International audience. PURPOSE The Lynch syndrome (LS)-glioma association is poorly documented. As for mismatch repair deficiency (MMRd) in glioma, a hallmark of LS-associated tumors, there are only limited data available. We determined MMRd and LS prevalence in a large series of unselected gliomas, and explored the associated characteristics. Both have major implications in terms of treatment, screening, and prevention. METHODS Somatic next-generation sequencing was performed on 1,225 treatment-naive adult gliomas referred between 2017 and June 2022. For gliomas with ≥1 MMR pathogenic variant (PV), MMR immunohistochemistry (IHC) was done. Gliomas with ≥1 PV and protein expression loss were considered MMRd. Eligible patients had germline testing. To further explore MMRd specifically in glioblastomas, isocitrate dehydrogenase (IDH)-wild type (wt), we performed IHC, and complementary sequencing when indicated, in a series of tumors diagnosed over the 2007-2021 period. RESULTS Nine gliomas were MMRd (9/1,225; 0.73%). Age at glioma diagnosis was <50 years for all but one case. Eight were glioblastomas, IDH-wt, and one was an astrocytoma, IDH-mutant. ATRX (n = 5) and TP53 (n = 8) PV were common. There was no TERT promoter PV or EGFR amplification. LS prevalence was 5/1,225 (0.41%). One 77-year-old patient was a known LS case. Four cases had a novel LS diagnosis, with germline PV in MSH2 (n = 3) and MLH1 (n = 1). One additional patient had PMS2-associated constitutional mismatch repair deficiency. Germline testing was negative in three MSH6-deficient tumors. In the second series of glioblastomas, IDH-wt, MMRd prevalence was 12.5% in the <40-year age group, 2.6% in the 40-49 year age group, and 1.6% the ≥50 year age group. CONCLUSION Screening for MMRd and LS should be systematic in glioblastomas, IDH-wt, diagnosed under age 50 years.

Suggestions

Du même auteur

Lobular breast cancer: incidence and genetic and non-genetic risk factors.

Archive ouverte | Dossus, Laure | CCSD

International audience. While most invasive breast cancers consist of carcinomas of the ductal type, about 10% are invasive lobular carcinomas. Invasive lobular and ductal carcinomas differ with respect to risk fact...

Overcoming the challenges associated with universal screening for Lynch syndrome in colorectal and endometrial cancer

Archive ouverte | Benusiglio, Patrick, R | CCSD

International audience

Survival outcomes associated with first-line procarbazine, CCNU, and Vincristine or Temozolomide in combination with radiotherapy in IDH-mutant 1p/19q-codeleted grade 3 oligodendroglioma

Archive ouverte | Kacimi, Salah Eddine O. | CCSD

International audience. Purpose: Patients with IDH-mutant 1p/19q-codeleted grade 3 oligodendroglioma (O3IDHmt/Codel) benefit from adding alkylating agent chemotherapy to radiotherapy (RT). However, the optimal chemo...

Chargement des enrichissements...